LLY Jan 2025 460.000 call
| Previous Close | 504.29 |
| Open | 504.29 |
| Bid | 469.00 |
| Ask | 476.85 |
| Strike | 460.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 504.29 - 504.29 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 66 |
Insider MonkeyIs Eli Lilly and Company (LLY) an Unstoppable Dividend Stocks to Buy?
We recently compiled a list of the 10 Unstoppable Dividend Stocks to Buy. In this article, we will have a look at where Eli Lilly and Company (NYSE:LLY) ranks among other unstoppable dividend stocks to buy. It’s undeniable that dividends have played a key role in the market’s returns over the past year. While they […]
PR NewswireFDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies.1 Eczema inflammation under the skin can lead to symptoms seen and felt on the outside. EBGLYSS works
ZacksRoche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.
